Which cardioprotective medications should be prescribed for adult patients with diabetes?

Cardioprotective Drugs in Diabetes

For adults with diabetes, prescribe SGLT-2 inhibitors or GLP-1 receptor agonists based on cardiovascular/kidney risk stratification, along with statins for all patients ≥40 years old. 1, 2

Risk-Stratified Approach to SGLT-2i and GLP-1RA

The selection of cardioprotective agents depends critically on the patient's cardiovascular and kidney disease risk profile 1:

Higher Risk Patients (STRONG recommendation)

Prescribe either SGLT-2 inhibitors OR GLP-1 receptor agonists for patients with:

• Established cardiovascular disease (CVD) at higher risk of complications, OR
• Chronic kidney disease (CKD) at higher risk of complications, OR
• Established heart failure

For these high-risk patients, add finerenone if CKD is present (weak recommendation) 1.

Recent real-world evidence shows GLP-1RAs provide the lowest MACE risk, followed by SGLT-2is, with the benefit of GLP-1RAs over SGLT-2is most pronounced in patients with baseline ASCVD, heart failure, age ≥65 years, or moderate kidney impairment 3. However, both classes demonstrate substantial cardiovascular protection.

Moderate Risk Patients (WEAK recommendation in favor)

Consider SGLT-2 inhibitors OR GLP-1 receptor agonists for patients with:

• More than 3 cardiovascular risk factors without established CVD or CKD, OR
• Established CVD and/or CKD at lower risk of complications

Lower Risk Patients (WEAK recommendation against)

Do not routinely prescribe SGLT-2i or GLP-1RA for patients with:

• Three or fewer cardiovascular risk factors
• No established CVD or CKD

The exception: prescribe tirzepatide across all risk strata if obesity is present (weak recommendation) 1.

Statin Therapy: Universal Foundation

All diabetic patients aged 40-75 years require statin therapy regardless of cardiovascular risk 2:

Age 40-75 Years Without ASCVD

• Moderate-intensity statin (e.g., atorvastatin 10-20 mg, rosuvastatin 5-10 mg)

Age 40-75 Years at Higher CV Risk

• High-intensity statin to reduce LDL cholesterol by ≥50% and achieve LDL <70 mg/dL
• High-intensity options: atorvastatin 40-80 mg or rosuvastatin 20-40 mg
• If LDL remains ≥70 mg/dL on maximum tolerated statin, add ezetimibe or PCSK9 inhibitor 2

Age 20-39 Years

• Consider statin if additional ASCVD risk factors present

Age >75 Years

• Continue statin if already prescribed 2

Practical Selection Between SGLT-2i and GLP-1RA

When both classes are appropriate, consider these factors 4:

Favor SGLT-2 inhibitors if:

• Heart failure is present (primary or secondary prevention)
• Patient managed primarily by cardiology
• Lower eGFR (though both have kidney benefits)

Favor GLP-1 receptor agonists if:

• Higher BMI/obesity is prominent
• Established ASCVD with age ≥65 years
• Patient managed primarily by endocrinology
• Maximum weight loss desired 3, 4

Critical Pitfalls to Avoid

1. Don't wait for cardiovascular events: The 2025 BMJ guideline emphasizes risk stratification BEFORE events occur, not just secondary prevention 1

2. Don't use DPP-4 inhibitors for cardioprotection: These have neutral cardiovascular effects and confer higher MACE risk compared to SGLT-2i and GLP-1RA 3, 5

3. Don't skip statins: Statins remain the cornerstone lipid therapy with proven mortality benefit independent of newer agents 2

4. Don't ignore kidney function: Both SGLT-2i and GLP-1RA provide renoprotection, but dosing adjustments may be needed 1

5. Monitor for euglycemic DKA with SGLT-2i: Though rare, this potentially dangerous adverse effect requires patient education 6

Mechanistic Rationale

Both SGLT-2i and GLP-1RA provide cardioprotection through glucose-independent mechanisms including potent antioxidant and anti-inflammatory properties, improved endothelial function, reduced thrombosis risk, and beneficial effects on blood pressure and weight 5, 7. SGLT-2 inhibitors particularly reduce hospitalization for heart failure, while GLP-1RAs show robust MACE reduction 8, 7.